{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:00:49Z","timestamp":1771642849048,"version":"3.50.1"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10787-025-02091-4","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:44:32Z","timestamp":1767591872000},"page":"967-983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium-glucose cotransporter-2 inhibitors and sepsis: a story with two tails or with one tail?"],"prefix":"10.1007","volume":"34","author":[{"given":"Baris","family":"Afsar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rengin Elsurer","family":"Afsar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista L.","family":"Lentine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2091_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/SHK.0000000000001504","volume":"54","author":"T Abe","year":"2020","unstructured":"Abe T, Kubo K, Izumoto S, Shimazu S, Goan A, Tanaka T, Koroki T, Saito K, Kawana R, Ochiai H (2020) Complement activation in human sepsis is related to sepsis-Induced disseminated intravascular coagulation. Shock 54:198\u2013204","journal-title":"Shock"},{"key":"2091_CR3","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.clnu.2023.10.004","volume":"42","author":"B Afsar","year":"2023","unstructured":"Afsar B, Afsar RE (2023a) Sodium-glucose co-transporter 2 inhibitors and sarcopenia: a controversy that must be solved. Clin Nutr 42:2338\u20132352","journal-title":"Clin Nutr"},{"key":"2091_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s43440-022-00442-4","volume":"75","author":"B Afsar","year":"2023","unstructured":"Afsar B, Afsar RE (2023b) Sodium-glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms. Pharmacol Rep 75:44\u201368","journal-title":"Pharmacol Rep"},{"key":"2091_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.mito.2021.02.016","volume":"58","author":"B Afsar","year":"2021","unstructured":"Afsar B, Hornum M, Afsar RE, Ertuglu LA, Ortiz A, Covic A, van Raalte DH, Cherney DZI, Kanbay M (2021) Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications. Mitochondrion 58:72\u201382","journal-title":"Mitochondrion"},{"key":"2091_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40200-024-01435-1","volume":"23","author":"B Afsar","year":"2024","unstructured":"Afsar B, Afsar RE, Lentine KL (2024) The impact of sodium-glucose cotransporter inhibitors on gut microbiota: a scoping review. J Diabetes Metab Disord 23:497\u2013508","journal-title":"J Diabetes Metab Disord"},{"key":"2091_CR8","doi-asserted-by":"crossref","unstructured":"Alanazi WA, Alharbi T, El-Nagar DM, Albogami AM, Alswayyed M (2023) Dapagliflozin Mitigates hypotension in lipopolysaccharide-induced acute inflammation independent of glycemia Level. Pharmaceutics 15","DOI":"10.3390\/pharmaceutics15061683"},{"key":"2091_CR7","doi-asserted-by":"publisher","first-page":"e18761429329635","DOI":"10.2174\/0118761429329635241016054513","volume":"17","author":"WA Alanazi","year":"2024","unstructured":"Alanazi WA, Alharbi T, Bin Anzan KM, Alyahiya MK, El-Nagar DM, Alanazi MM, Almutairi MM, Alhamami HN, Albogami AM, Mohany M (2024) The role of Dapagliflozin in the modulation of hypothermia and renal injury caused by septic shock in euglycemic and hyperglycemic rat models. Curr Mol Pharmacol 17:e18761429329635","journal-title":"Curr Mol Pharmacol"},{"key":"2091_CR9","doi-asserted-by":"crossref","unstructured":"Ang\u00e9 M, Castanares-Zapatero D, De Poortere J, Dufeys C, Courtoy GE, Bouzin C, Quarck R, Bertrand L, Beauloye C, Horman S (2020) \u03b11AMP-Activated protein kinase protects against Lipopolysaccharide-Induced endothelial barrier disruption via junctional reinforcement and activation of the p38 MAPK\/HSP27 pathway. Int J Mol Sci 21","DOI":"10.3390\/ijms21155581"},{"key":"2091_CR10","doi-asserted-by":"publisher","first-page":"13700","DOI":"10.1038\/s41598-021-93156-1","volume":"11","author":"M Ang\u00e9","year":"2021","unstructured":"Ang\u00e9 M, De Poortere J, Ginion A, Battault S, Dechamps M, Muccioli GG, Roumain M, Morelle J, Druart S, Mathivet T, Bertrand L, Castanares-Zapatero D, Horman S, Beauloye C (2021) Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial \u03b11AMPK. Sci Rep 11:13700","journal-title":"Sci Rep"},{"key":"2091_CR11","doi-asserted-by":"publisher","first-page":"109691","DOI":"10.1016\/j.celrep.2021.109691","volume":"36","author":"FF Anh\u00ea","year":"2021","unstructured":"Anh\u00ea FF, Barra NG, Cavallari JF, Henriksbo BD, Schertzer JD (2021) Metabolic endotoxemia is dictated by the type of lipopolysaccharide. Cell Rep 36:109691","journal-title":"Cell Rep"},{"key":"2091_CR12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pi\u00f1a IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461","journal-title":"N Engl J Med"},{"key":"2091_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40256-024-00673-1","volume":"24","author":"D Aristiz\u00e1bal-Colorado","year":"2024","unstructured":"Aristiz\u00e1bal-Colorado D, Ocampo-Posada M, Rivera-Mart\u00ednez WA, Corredor-Rengifo D, Rico-Fontalvo J, G\u00f3mez-Mesa JE, Duque-Ossman JJ, Abreu-Lomba A (2024) SGLT2 inhibitors and how they work beyond the glucosuric Effect. State of the Art. Am J Cardiovasc Drugs 24:707\u2013718","journal-title":"Am J Cardiovasc Drugs"},{"key":"2091_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4266\/acc.2023.01046","volume":"39","author":"N Ashcherkin","year":"2024","unstructured":"Ashcherkin N, Abdalla AA, Gupta S, Bhatt S, Yee CI, Cartin-Ceba R (2024) Are sodium-glucose co-transporter-2 inhibitors associated with improved outcomes in diabetic patients admitted to intensive care units with septic shock? Acute Crit Care 39:251\u2013256","journal-title":"Acute Crit Care"},{"key":"2091_CR15","doi-asserted-by":"publisher","first-page":"110114","DOI":"10.1016\/j.isci.2024.110114","volume":"27","author":"PA Assis","year":"2024","unstructured":"Assis PA, Allen RM, Schaller MA, Kunkel SL, Bermick JR (2024) Metabolic reprogramming and dysregulated IL-17 production impairs CD4 T cell function post sepsis. iScience 27:110114","journal-title":"iScience"},{"key":"2091_CR16","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s40618-023-02162-9","volume":"46","author":"G Bendotti","year":"2023","unstructured":"Bendotti G, Montefusco L, Pastore I, Lazzaroni E, Lunati ME, Fiorina P (2023) The anti-inflammatory and immunological properties of SGLT-2 inhibitors. J Endocrinol Invest 46:2445\u20132452","journal-title":"J Endocrinol Invest"},{"key":"2091_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, D\u00edaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384:129\u2013139","journal-title":"N Engl J Med"},{"key":"2091_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s13054-023-04762-6","volume":"27","author":"C Bode","year":"2023","unstructured":"Bode C, Weis S, Sauer A, Wendel-Garcia P, David S (2023) Targeting the host response in sepsis: current approaches and future evidence. Crit Care 27:478","journal-title":"Crit Care"},{"key":"2091_CR19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.humimm.2021.03.004","volume":"82","author":"S Borzouei","year":"2021","unstructured":"Borzouei S, Moghimi H, Zamani A, Behzad M (2021) Changes in T helper cell-related factors in patients with type 2 diabetes mellitus after empagliflozin therapy. Hum Immunol 82:422\u2013428","journal-title":"Hum Immunol"},{"key":"2091_CR20","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1097\/CCM.0b013e31829866dc","volume":"41","author":"D Castanares-Zapatero","year":"2013","unstructured":"Castanares-Zapatero D, Bouleti C, Sommereyns C, Gerber B, Lecut C, Mathivet T, Horckmans M, Communi D, Foretz M, Vanoverschelde JL, Germain S, Bertrand L, Laterre PF, Oury C, Viollet B, Horman S, Beauloye C (2013) Connection between cardiac vascular permeability, myocardial edema, and inflammation during sepsis: role of the \u03b11AMP-activated protein kinase isoform. Crit Care Med 41:e411\u2013422","journal-title":"Crit Care Med"},{"key":"2091_CR21","doi-asserted-by":"publisher","first-page":"729334","DOI":"10.3389\/fphar.2021.729334","volume":"12","author":"DY Chang","year":"2021","unstructured":"Chang DY, Li XQ, Chen M, Zhao MH (2021) Dapagliflozin ameliorates diabetic kidney disease via upregulating Crry and alleviating complement Over-activation in db\/db mice. Front Pharmacol 12:729334","journal-title":"Front Pharmacol"},{"key":"2091_CR22","doi-asserted-by":"publisher","first-page":"C951","DOI":"10.1152\/ajpcell.00528.2022","volume":"324","author":"X Chen","year":"2023","unstructured":"Chen X, Deli\u0107 D, Cao Y, Shen L, Shao Q, Zhang Z, Wu H, Hasan AA, Reichetzeder C, Gaballa MMS, Kr\u00e4mer BK, Klein T, Yin L, He B, Morgera S, Hocher B (2023) Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system. Am J Physiol Cell Physiol 324:C951\u2013c962","journal-title":"Am J Physiol Cell Physiol"},{"key":"2091_CR23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.7150\/ijms.69031","volume":"19","author":"PJ Chi","year":"2022","unstructured":"Chi PJ, Lee CJ, Hsieh YJ, Lu CW, Hsu BG (2022) Dapagliflozin ameliorates lipopolysaccharide related acute kidney injury in mice with Streptozotocin-induced diabetes mellitus. Int J Med Sci 19:729\u2013739","journal-title":"Int J Med Sci"},{"key":"2091_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/heartjnl-2022-321545","volume":"109","author":"CH Chiang","year":"2023","unstructured":"Chiang CH, Chiang CH, Chiang CH, Ma KS, Peng CY, Hsia YP, Horng CS, Chen CY, Chang YC, See XY, Chen YJ, Wang SS, Suero-Abreu GA, Peterson LR, Thavendiranathan P, Armand P, Peng CM, Shiah HS, Neilan TG (2023) Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart 109:470\u2013477","journal-title":"Heart"},{"key":"2091_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11010-019-03555-2","volume":"459","author":"S Cooper","year":"2019","unstructured":"Cooper S, Teoh H, Campeau MA, Verma S, Leask RL (2019) Empagliflozin restores the integrity of the endothelial glycocalyx in vitro. Mol Cell Biochem 459:121\u2013130","journal-title":"Mol Cell Biochem"},{"key":"2091_CR26","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1096\/fj.10-179218","volume":"25","author":"J Creighton","year":"2011","unstructured":"Creighton J, Jian M, Sayner S, Alexeyev M, Insel PA (2011) Adenosine monophosphate-activated kinase alpha1 promotes endothelial barrier repair. Faseb J 25:3356\u20133365","journal-title":"Faseb J"},{"key":"2091_CR27","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/10512","volume":"5","author":"BJ Czermak","year":"1999","unstructured":"Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM, Schmal H, Friedl HP, Ward PA (1999) Protective effects of C5a Blockade in sepsis. Nat Med 5:788\u2013792","journal-title":"Nat Med"},{"key":"2091_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1164\/rccm.200109-016OC","volume":"166","author":"D De Backer","year":"2002","unstructured":"De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL (2002) Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166:98\u2013104","journal-title":"Am J Respir Crit Care Med"},{"key":"2091_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13054-023-04344-6","volume":"27","author":"AH de Nooijer","year":"2023","unstructured":"de Nooijer AH, Kotsaki A, Kranidioti E, Kox M, Pickkers P, Toonen EJM, Giamarellos-Bourboulis EJ, Netea MG (2023) Complement activation in severely ill patients with sepsis: no relationship with inflammation and disease severity. Crit Care 27:63","journal-title":"Crit Care"},{"key":"2091_CR30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/SHK.0000000000001549","volume":"54","author":"H Deng","year":"2020","unstructured":"Deng H, Wu L, Liu M, Zhu L, Chen Y, Zhou H, Shi X, Wei J, Zheng L, Hu X, Wang M, He Z, Lv X, Yang H (2020) Bone marrow mesenchymal stem Cell-Derived exosomes attenuate LPS-Induced ARDS by modulating macrophage polarization through inhibiting Glycolysis in macrophages. Shock 54:828\u2013843","journal-title":"Shock"},{"key":"2091_CR31","doi-asserted-by":"publisher","first-page":"100091","DOI":"10.1016\/j.mbplus.2021.100091","volume":"12","author":"CC Drost","year":"2021","unstructured":"Drost CC, Rovas A, K\u00fcmpers P (2021) Protection and rebuilding of the endothelial glycocalyx in sepsis - Science or fiction? Matrix Biol Plus 12:100091","journal-title":"Matrix Biol Plus"},{"key":"2091_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/ejhf.2409","volume":"24","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Anker SD, Butler J, Filippatos G, Iwata T, Salsali A, Zeller C, Pocock SJ, Zannad F, Packer M (2022) Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced. Eur J Heart Fail 24:708\u2013715","journal-title":"Eur J Heart Fail"},{"key":"2091_CR33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11606-024-09073-2","volume":"40","author":"R Garg","year":"2025","unstructured":"Garg R, Sood N, Bansal O, Hoskote A (2025) Euglycemic ketoacidosis associated with SGLT-2 inhibitors in Non-diabetic Patients-A narrative review. J Gen Intern Med 40:437\u2013442","journal-title":"J Gen Intern Med"},{"key":"2091_CR34","doi-asserted-by":"crossref","unstructured":"Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A, Chaudhuri A, Dandona P (2020) Dapagliflozin suppresses Hepcidin and increases erythropoiesis. J Clin Endocrinol Metab 105","DOI":"10.1210\/clinem\/dgaa057"},{"key":"2091_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.devcel.2013.08.020","volume":"26","author":"M Giannotta","year":"2013","unstructured":"Giannotta M, Trani M, Dejana E (2013) VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell 26:441\u2013454","journal-title":"Dev Cell"},{"key":"2091_CR36","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1007\/s00134-024-07586-2","volume":"50","author":"M Girardis","year":"2024","unstructured":"Girardis M, David S, Ferrer R, Helms J, Juffermans NP, Martin-Loeches I, Povoa P, Russell L, Shankar-Hari M, Iba T, Coloretti I, Parchim N, Nielsen ND (2024) Understanding, assessing and treating immune, endothelial and haemostasis dysfunctions in bacterial sepsis. Intensive Care Med 50:1580\u20131592","journal-title":"Intensive Care Med"},{"key":"2091_CR37","doi-asserted-by":"publisher","first-page":"100864","DOI":"10.1016\/j.blre.2021.100864","volume":"50","author":"M Giustozzi","year":"2021","unstructured":"Giustozzi M, Ehrlinder H, Bongiovanni D, Borovac JA, Guerreiro RA, G\u0105secka A, Papakonstantinou PE, Parker WAE (2021) Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment. Blood Rev 50:100864","journal-title":"Blood Rev"},{"key":"2091_CR38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW (2018) Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 20:479\u2013487","journal-title":"Diabetes Obes Metab"},{"key":"2091_CR39","doi-asserted-by":"publisher","first-page":"175930","DOI":"10.1016\/j.ejphar.2023.175930","volume":"955","author":"X Han","year":"2023","unstructured":"Han X, Liu X, Zhao X, Wang X, Sun Y, Qu C, Liang J, Yang B (2023) Dapagliflozin ameliorates sepsis-induced heart injury by inhibiting cardiomyocyte apoptosis and electrical remodeling through the PI3K\/Akt pathway. Eur J Pharmacol 955:175930","journal-title":"Eur J Pharmacol"},{"key":"2091_CR40","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3389\/fimmu.2019.00891","volume":"10","author":"F Haussner","year":"2019","unstructured":"Haussner F, Chakraborty S, Halbgebauer R, Huber-Lang M (2019) Challenge to the intestinal mucosa during sepsis. Front Immunol 10:891","journal-title":"Front Immunol"},{"key":"2091_CR41","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.2337\/db16-0058","volume":"65","author":"SA Hawley","year":"2016","unstructured":"Hawley SA, Ford RJ, Smith BK, Gowans GJ, Mancini SJ, Pitt RD, Day EA, Salt IP, Steinberg GR, Hardie DG (2016) The Na+\/Glucose cotransporter inhibitor Canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 65:2784\u20132794","journal-title":"Diabetes"},{"key":"2091_CR42","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00592-022-02015-6","volume":"60","author":"Z He","year":"2023","unstructured":"He Z, Lam K, Zhao W, Yang S, Li Y, Mo J, Gao S, Liang D, Qiu K, Huang M, Wu J (2023) SGLT-2 inhibitors and euglycemic diabetic ketoacidosis\/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment. Acta Diabetol 60:401\u2013411","journal-title":"Acta Diabetol"},{"key":"2091_CR43","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sj\u00f6str\u00f6m CD, Toto RD, Langkilde AM, Wheeler DC (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446","journal-title":"N Engl J Med"},{"key":"2091_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/thorax-2024-221906","volume":"80","author":"AE Henney","year":"2024","unstructured":"Henney AE, Riley DR, Hydes TJ, Anson M, Ibarburu GH, Frost F, Alam U, Cuthbertson DJ (2024) Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data. Thorax 80:32\u201341","journal-title":"Thorax"},{"key":"2091_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117\u2013127","journal-title":"N Engl J Med"},{"key":"2091_CR45","unstructured":"Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R (2024) Long-Term effects of empagliflozin in patients with chronic kidney disease. N Engl J Med"},{"key":"2091_CR47","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nri3552","volume":"13","author":"RS Hotchkiss","year":"2013","unstructured":"Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13:862\u2013874","journal-title":"Nat Rev Immunol"},{"key":"2091_CR49","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00210-023-02685-1","volume":"397","author":"WS Hu","year":"2024","unstructured":"Hu WS, Lin CL (2024) Sodium-glucose cotransporter-2 inhibitor in risk of sepsis\/septic shock among patients with type 2 diabetes mellitus-a retrospective analysis of nationwide medical claims data. Naunyn Schmiedebergs Arch Pharmacol 397:1623\u20131631","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2091_CR48","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13054-024-05069-w","volume":"28","author":"D Hu","year":"2024","unstructured":"Hu D, Sheeja Prabhakaran H, Zhang YY, Luo G, He W, Liou YC (2024) Mitochondrial dysfunction in sepsis: mechanisms and therapeutic perspectives. Crit Care 28:292","journal-title":"Crit Care"},{"key":"2091_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbi.2017.11.003","volume":"72","author":"J Huang","year":"2018","unstructured":"Huang J, Liu K, Zhu S, Xie M, Kang R, Cao L, Tang D (2018) AMPK regulates immunometabolism in sepsis. Brain Behav Immun 72:89\u2013100","journal-title":"Brain Behav Immun"},{"key":"2091_CR51","doi-asserted-by":"publisher","first-page":"e015716","DOI":"10.1161\/JAHA.119.015716","volume":"9","author":"I Ikonomidis","year":"2020","unstructured":"Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V (2020) Effects of Glucagon-Like Peptide-1 receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and their combination on endothelial Glycocalyx, arterial Function, and myocardial work index in patients with type 2 diabetes mellitus after 12-Month treatment. J Am Heart Assoc 9:e015716","journal-title":"J Am Heart Assoc"},{"key":"2091_CR52","doi-asserted-by":"crossref","unstructured":"Ilhan I, Karakuyu NF, Karabacak P, Milletsever A, Kolay O, Baysal G, Asc\u0131 H (2025) Effect of Dapagliflozin on sepsis-induced kidney injury in a rat model: modulation of the NLRP3 pathway. Immunopharmacol Immunotoxicol :1\u20138","DOI":"10.1080\/08923973.2025.2519597"},{"key":"2091_CR1","unstructured":"Nuffield Department of Population Health Renal Studies Group and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium (2022) Impact of diabetes on the Effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400:1788\u20131801"},{"issue":"Suppl 4","key":"2091_CR53","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1186\/cc3753","volume":"9","author":"C Ince","year":"2005","unstructured":"Ince C (2005) The microcirculation is the motor of sepsis. Crit Care 9(Suppl 4):S13\u201319","journal-title":"Crit Care"},{"key":"2091_CR54","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.cmet.2023.05.001","volume":"35","author":"BJ Jenkins","year":"2023","unstructured":"Jenkins BJ, Blagih J, Ponce-Garcia FM, Canavan M, Gudgeon N, Eastham S, Hill D, Hanlon MM, Ma EH, Bishop EL, Rees A, Cronin JG, Jury EC, Dimeloe SK, Veale DJ, Thornton CA, Vousden KH, Finlay DK, Fearon U, Jones GW, Sinclair LV, Vincent EE, Jones N (2023) Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity. Cell Metab 35:1132\u20131146e1139","journal-title":"Cell Metab"},{"key":"2091_CR55","doi-asserted-by":"publisher","first-page":"L71","DOI":"10.1152\/ajplung.00227.2015","volume":"310","author":"MY Jian","year":"2016","unstructured":"Jian MY, Liu Y, Li Q, Wolkowicz P, Alexeyev M, Zmijewski J, Creighton J (2016) N-cadherin coordinates AMP kinase-mediated lung vascular repair. Am J Physiol Lung Cell Mol Physiol 310:L71\u201385","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2091_CR56","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1177\/09603271211010906","volume":"40","author":"AM Kabel","year":"2021","unstructured":"Kabel AM, Salama SA (2021) Effect of taxifolin\/dapagliflozin combination on colistin-induced nephrotoxicity in rats. Hum Exp Toxicol 40:1767\u20131780","journal-title":"Hum Exp Toxicol"},{"key":"2091_CR57","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s11255-021-02943-2","volume":"54","author":"M Kanbay","year":"2022","unstructured":"Kanbay M, Tapoi L, Ureche C, Tanriover C, Cevik E, Demiray A, Afsar B, Cherney DZI, Covic A (2022) Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis. Int Urol Nephrol 54:827\u2013841","journal-title":"Int Urol Nephrol"},{"key":"2091_CR58","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1055\/a-2202-8544","volume":"44","author":"J Kappelmayer","year":"2024","unstructured":"Kappelmayer J, Debreceni IB, Fejes Z, Nagy B Jr. (2024) Inflammation, Sepsis, and the coagulation system. Hamostaseologie 44:268\u2013276","journal-title":"Hamostaseologie"},{"key":"2091_CR59","doi-asserted-by":"publisher","first-page":"111709","DOI":"10.1016\/j.intimp.2024.111709","volume":"130","author":"LH Khedr","year":"2024","unstructured":"Khedr LH, Rahmo RM, Eldemerdash OM, Helmy EM, Ramzy FA, Lotfy GH, Zakaria HA, Gad MM, Youhanna MM, Samaan MH, Thabet NW, Ghazal RH, Rabie MA (2024) Implication of M2 macrophage on NLRP3 inflammasome signaling in mediating the neuroprotective effect of Canagliflozin against methotrexate-induced cognitive impairment. Int Immunopharmacol 130:111709","journal-title":"Int Immunopharmacol"},{"key":"2091_CR60","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00011-023-01796-y","volume":"72","author":"YJ Kim","year":"2023","unstructured":"Kim YJ, Jin J, Kim DH, Kim D, Lee YM, Byun JK, Choi YK, Park KG (2023) SGLT2 inhibitors prevent LPS-induced M1 macrophage polarization and alleviate inflammatory bowel disease by downregulating NHE1 expression. Inflamm Res 72:1981\u20131997","journal-title":"Inflamm Res"},{"key":"2091_CR61","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1007\/s00125-021-05498-0","volume":"64","author":"C Kohlmorgen","year":"2021","unstructured":"Kohlmorgen C, Gerfer S, Feldmann K, Twarock S, Hartwig S, Lehr S, Klier M, Kr\u00fcger I, Helten C, Keul P, Kahl S, Polzin A, Elvers M, Fl\u00f6gel U, Kelm M, Levkau B, Roden M, Fischer JW, Grandoch M (2021) Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. Diabetologia 64:1834\u20131849","journal-title":"Diabetologia"},{"key":"2091_CR62","doi-asserted-by":"publisher","first-page":"EVIDoa2300049","DOI":"10.1056\/EVIDoa2300049","volume":"2","author":"A Koshino","year":"2023","unstructured":"Koshino A, Schechter M, Chertow GM, Vart P, Jongs N, Toto RD, Rossing P, Correa-Rotter R, McMurray JJV, G\u00f3rriz JL, Isidto R, Kashihara N, Langkilde AM, Wheeler DC, Heerspink HJL (2023) Dapagliflozin and anemia in patients with chronic kidney disease. NEJM Evid 2:EVIDoa2300049","journal-title":"NEJM Evid"},{"key":"2091_CR63","doi-asserted-by":"publisher","first-page":"107087","DOI":"10.1016\/j.intimp.2020.107087","volume":"89","author":"V Kumar","year":"2020","unstructured":"Kumar V (2020) Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future Immunomodulatory targets. Int Immunopharmacol 89:107087","journal-title":"Int Immunopharmacol"},{"key":"2091_CR64","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13098-024-01354-4","volume":"16","author":"HH Kuo","year":"2024","unstructured":"Kuo HH, Wang KT, Chen HH, Lai ZY, Lin PL, Chuang YJ, Liu LY (2024) Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis. Diabetol Metab Syndr 16:108","journal-title":"Diabetol Metab Syndr"},{"key":"2091_CR65","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853\u2013862","journal-title":"Diabetes Obes Metab"},{"key":"2091_CR66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.thromres.2019.11.011","volume":"185","author":"MA Laursen","year":"2020","unstructured":"Laursen MA, Larsen JB, Larsen KM, Hvas AM (2020) Platelet function in patients with septic shock. Thromb Res 185:33\u201342","journal-title":"Thromb Res"},{"key":"2091_CR67","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1210\/clinem\/dgac558","volume":"107","author":"HL Li","year":"2022","unstructured":"Li HL, Tse YK, Chandramouli C, Hon NW, Cheung CL, Lam LY, Wu M, Huang JY, Yu SY, Leung KL, Fei Y, Feng Q, Ren Q, Cheung BMY, Tse HF, Verma S, Lam CSP, Yiu KH (2022) Sodium-Glucose cotransporter 2 inhibitors and the risk of pneumonia and septic shock. J Clin Endocrinol Metab 107:3442\u20133451","journal-title":"J Clin Endocrinol Metab"},{"key":"2091_CR68","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1038\/s41401-024-01389-3","volume":"45","author":"XF Lin","year":"2024","unstructured":"Lin XF, Cui XN, Yang J, Jiang YF, Wei TJ, Xia L, Liao XY, Li F, Wang DD, Li J, Wu Q, Yin DS, Le YY, Yang K, Wei R, Hong TP (2024) SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing Glycolysis and modulating macrophage polarization. Acta Pharmacol Sin 45:2579\u20132597","journal-title":"Acta Pharmacol Sin"},{"key":"2091_CR70","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s00018-022-04490-0","volume":"79","author":"J Liu","year":"2022","unstructured":"Liu J, Zhou G, Wang X, Liu D (2022) Metabolic reprogramming consequences of sepsis: adaptations and contradictions. Cell Mol Life Sci 79:456","journal-title":"Cell Mol Life Sci"},{"key":"2091_CR69","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13098-023-01229-0","volume":"15","author":"J Liu","year":"2023","unstructured":"Liu J, Chang X, Ding X, He X, Wang J, Wang G (2023) Effect of Dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes. Diabetol Metab Syndr 15:251","journal-title":"Diabetol Metab Syndr"},{"key":"2091_CR71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","volume":"66","author":"BC Lupsa","year":"2023","unstructured":"Lupsa BC, Kibbey RG, Inzucchi SE (2023) Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia 66:23\u201332","journal-title":"Diabetologia"},{"key":"2091_CR72","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10787-020-00732-4","volume":"29","author":"ZH Maayah","year":"2021","unstructured":"Maayah ZH, Ferdaoussi M, Takahara S, Soni S, Dyck JRB (2021) Empagliflozin suppresses inflammation and protects against acute septic renal injury. Inflammopharmacology 29:269\u2013279","journal-title":"Inflammopharmacology"},{"key":"2091_CR73","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/SHK.0000000000002291","volume":"61","author":"H Madarati","year":"2024","unstructured":"Madarati H, Singh K, Sparring T, Andrisani P, Liaw PC, Fox-Robichaud AE, Kretz CA (2024) Reviewing the dysregulation of adamts13 and vwf in sepsis. Shock 61:189\u2013196","journal-title":"Shock"},{"key":"2091_CR74","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","volume":"8","author":"SJ Mancini","year":"2018","unstructured":"Mancini SJ, Boyd D, Katwan OJ, Strembitska A, Almabrouk TA, Kennedy S, Palmer TM, Salt IP (2018) Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep 8:5276","journal-title":"Sci Rep"},{"key":"2091_CR75","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41598-023-28225-8","volume":"13","author":"N Marci\u0144czyk","year":"2023","unstructured":"Marci\u0144czyk N, Misztal T, Chabielska E, Gromotowicz-Pop\u0142awska A (2023) Sex-dependent effects of Canagliflozin and Dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice. Sci Rep 13:932","journal-title":"Sci Rep"},{"key":"2091_CR76","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1089\/dia.2019.0212","volume":"21","author":"T Maruyama","year":"2019","unstructured":"Maruyama T, Takashima H, Oguma H, Nakamura Y, Ohno M, Utsunomiya K, Furukawa T, Tei R, Abe M (2019) Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease. Diabetes Technol Ther 21:713\u2013720","journal-title":"Diabetes Technol Ther"},{"key":"2091_CR77","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1681\/ASN.0000000000000271","volume":"35","author":"KJ Mayne","year":"2024","unstructured":"Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, Stegbauer J, Judge PK, Preiss D, Emberson J, Trinca D, Dayanandan R, Lee R, Nolan J, Omata A, Green JB, Cherney DZI, Hooi LS, Pontremoli R, Tuttle KR, Lees JS, Mark PB, Davies SJ, Hauske SJ, Steubl D, Br\u00fcckmann M, Landray MJ, Baigent C, Haynes R, Herrington WG (2024) Effects of empagliflozin on fluid Overload, Weight, and blood pressure in CKD. J Am Soc Nephrol 35:202\u2013215","journal-title":"J Am Soc Nephrol"},{"key":"2091_CR78","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3389\/fimmu.2020.01043","volume":"11","author":"MA McBride","year":"2020","unstructured":"McBride MA, Owen AM, Stothers CL, Hernandez A, Luan L, Burelbach KR, Patil TK, Bohannon JK, Sherwood ER, Patil NK (2020) The metabolic basis of immune dysfunction following sepsis and trauma. Front Immunol 11:1043","journal-title":"Front Immunol"},{"key":"2091_CR79","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13054-024-04875-6","volume":"28","author":"RR McMullan","year":"2024","unstructured":"McMullan RR, McAuley DF, O\u2019Kane CM, Silversides JA (2024) Vascular leak in sepsis: physiological basis and potential therapeutic advances. Crit Care 28:97","journal-title":"Crit Care"},{"key":"2091_CR80","doi-asserted-by":"publisher","first-page":"16113","DOI":"10.1038\/s41598-018-34305-x","volume":"8","author":"Y Miyachi","year":"2018","unstructured":"Miyachi Y, Tsuchiya K, Shiba K, Mori K, Komiya C, Ogasawara N, Ogawa Y (2018) A reduced M1-like\/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 Inhibition. Sci Rep 8:16113","journal-title":"Sci Rep"},{"key":"2091_CR81","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/CCM.0000000000005869","volume":"51","author":"PY Ng","year":"2023","unstructured":"Ng PY, Ng AK, Ip A, Wu MZ, Guo R, Yiu KH (2023) Risk of ICU admission and related mortality in patients with Sodium-Glucose cotransporter 2 inhibitors and dipeptidyl Peptidase-4 inhibitors: a territory-wide retrospective cohort study. Crit Care Med 51:1074\u20131085","journal-title":"Crit Care Med"},{"key":"2091_CR82","doi-asserted-by":"publisher","first-page":"107773","DOI":"10.1016\/j.intimp.2021.107773","volume":"96","author":"Y Niu","year":"2021","unstructured":"Niu Y, Chen Y, Sun P, Wang Y, Luo J, Ding Y, Xie W (2021) Intragastric and atomized administration of Canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: a potential COVID-19 treatment. Int Immunopharmacol 96:107773","journal-title":"Int Immunopharmacol"},{"key":"2091_CR83","doi-asserted-by":"publisher","first-page":"111649","DOI":"10.1016\/j.biopha.2021.111649","volume":"139","author":"T Nozu","year":"2021","unstructured":"Nozu T, Miyagishi S, Ishioh M, Takakusaki K, Okumura T (2021) Phlorizin attenuates visceral hypersensitivity and colonic hyperpermeability in a rat model of irritable bowel syndrome. Biomed Pharmacother 139:111649","journal-title":"Biomed Pharmacother"},{"key":"2091_CR84","doi-asserted-by":"publisher","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","volume":"309","author":"J O\u2019Neill","year":"2015","unstructured":"O\u2019Neill J, Fasching A, Pihl L, Patinha D, Franz\u00e9n S, Palm F (2015) Acute SGLT Inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Ren Physiol 309:F227\u2013234","journal-title":"Am J Physiol Ren Physiol"},{"key":"2091_CR85","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","volume":"10","author":"M Orecchioni","year":"2019","unstructured":"Orecchioni M, Ghosheh Y, Pramod AB, Ley K (2019) Macrophage polarization: different gene signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively activated macrophages. Front Immunol 10:1084","journal-title":"Front Immunol"},{"key":"2091_CR86","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jacbts.2020.05.006","volume":"5","author":"M Packer","year":"2020","unstructured":"Packer M (2020) Mutual antagonism of Hypoxia-Inducible factor isoforms in Cardiac, Vascular, and renal disorders. JACC Basic Transl Sci 5:961\u2013968","journal-title":"JACC Basic Transl Sci"},{"key":"2091_CR87","doi-asserted-by":"crossref","unstructured":"Pignatelli P, Baratta F, Buzzetti R, D\u2019Amico A, Castellani V, Bartimoccia S, Siena A, D\u2019Onofrio L, Maddaloni E, Pingitore A, Chiariello GA, Santilli F, Pastori D, Cocomello N, Violi F, Del Ben M, Cammisotto V, Carnevale R (2022) The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study. Antioxidants (Basel) 11","DOI":"10.3390\/antiox11101878"},{"key":"2091_CR88","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB (2018) SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 55:503\u2013514","journal-title":"Acta Diabetol"},{"key":"2091_CR89","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/bjh.18293","volume":"198","author":"J Qin","year":"2022","unstructured":"Qin J, Liu Q, Liu A, Leng S, Wang S, Li C, Ma J, Peng J, Xu M (2022) Empagliflozin modulates CD4(+) T-cell differentiation via metabolic reprogramming in immune thrombocytopenia. Br J Haematol 198:765\u2013775","journal-title":"Br J Haematol"},{"key":"2091_CR90","doi-asserted-by":"publisher","first-page":"eadn9285","DOI":"10.1126\/scitranslmed.adn9285","volume":"16","author":"T Rahmel","year":"2024","unstructured":"Rahmel T, Effinger D, Bracht T, Griep L, Koos B, Sitek B, H\u00fcbner M, Hirschberger S, Basten J, Timmesfeld N, Adamzik M, Kreth S (2024) An open-label, randomized controlled trial to assess a ketogenic diet in critically ill patients with sepsis. Sci Transl Med 16:eadn9285","journal-title":"Sci Transl Med"},{"key":"2091_CR91","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1097\/01.CCM.0000138558.16257.3F","volume":"32","author":"Y Sakr","year":"2004","unstructured":"Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL (2004) Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 32:1825\u20131831","journal-title":"Crit Care Med"},{"key":"2091_CR92","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ahj.2020.12.007","volume":"233","author":"HM Salah","year":"2021","unstructured":"Salah HM, Al\u2019Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, Mounsey JP, Greene SJ, McGuire DK, Lopes RD, Fudim M (2021) Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: a meta-analysis update. Am Heart J 233:86\u201391","journal-title":"Am Heart J"},{"key":"2091_CR93","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano M, Goto S (2019) Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139:1985\u20131987","journal-title":"Circulation"},{"key":"2091_CR94","doi-asserted-by":"crossref","unstructured":"Santacroce E, D\u2019Angerio M, Ciobanu AL, Masini L, Lo Tartaro D, Coloretti I, Busani S, Rubio I, Meschiari M, Franceschini E, Mussini C, Girardis M, Gibellini L, Cossarizza A, De Biasi S (2024) Advances and challenges in sepsis management: modern tools and future directions. Cells 13","DOI":"10.3390\/cells13050439"},{"key":"2091_CR95","first-page":"406","volume":"30","author":"SJ Scherger","year":"2024","unstructured":"Scherger SJ, Kalil AC (2024) Sepsis phenotypes, subphenotypes, and endotypes: are they ready for bedside care? Curr Opin Crit Care 30:406\u2013413","journal-title":"Curr Opin Crit Care"},{"key":"2091_CR96","doi-asserted-by":"publisher","first-page":"L518","DOI":"10.1152\/ajplung.00369.2020","volume":"319","author":"LJ Schlapbach","year":"2020","unstructured":"Schlapbach LJ, Kissoon N, Alhawsawi A, Aljuaid MH, Daniels R, Gorordo-Delsol LA, Machado F, Malik I, Nsutebu EF, Finfer S, Reinhart K (2020) World sepsis day: a global agenda to target a leading cause of morbidity and mortality. Am J Physiol Lung Cell Mol Physiol 319:L518\u2013l522","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2091_CR97","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.molimm.2024.02.006","volume":"167","author":"W Sheng","year":"2024","unstructured":"Sheng W, Yu J, Zhang H, Zhang J (2024) Empagliflozin attenuates inflammation levels in autoimmune myocarditis through the STAT3 pathway and macrophage phenotype transformation. Mol Immunol 167:43\u201352","journal-title":"Mol Immunol"},{"key":"2091_CR98","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801\u2013810","journal-title":"JAMA"},{"key":"2091_CR99","doi-asserted-by":"publisher","first-page":"e0247017","DOI":"10.1371\/journal.pone.0247017","volume":"16","author":"K Singh","year":"2021","unstructured":"Singh K, Kwong AC, Madarati H, Kunasekaran S, Sparring T, Fox-Robichaud AE, Liaw PC, Kretz CA (2021) Characterization of ADAMTS13 and von Willebrand factor levels in septic and non-septic ICU patients. PLoS ONE 16:e0247017","journal-title":"PLoS ONE"},{"key":"2091_CR100","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O\u2019Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilder\u00e4ng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098","journal-title":"N Engl J Med"},{"key":"2091_CR101","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1128\/cdli.3.2.175-183.1996","volume":"3","author":"S St\u00f6ve","year":"1996","unstructured":"St\u00f6ve S, Welte T, Wagner TO, Kola A, Klos A, Bautsch W, K\u00f6hl J (1996) Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol 3:175\u2013183","journal-title":"Clin Diagn Lab Immunol"},{"key":"2091_CR102","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/cpt.3194","volume":"115","author":"GSQ Tan","year":"2024","unstructured":"Tan GSQ, Morton JI, Wood S, Shaw JE, Magliano DJ, Ilom\u00e4ki J (2024) SGLT-2 inhibitor use and Cause-Specific hospitalization rates: an Outcome-Wide study to identify novel associations of SGLT-2 inhibitors. Clin Pharmacol Ther 115:1304\u20131315","journal-title":"Clin Pharmacol Ther"},{"key":"2091_CR103","doi-asserted-by":"crossref","unstructured":"Tuttle KR (2023) Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors. J Clin Invest 133","DOI":"10.1172\/JCI167700"},{"key":"2091_CR104","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.4049\/jimmunol.1200534","volume":"190","author":"H Unnewehr","year":"2013","unstructured":"Unnewehr H, Rittirsch D, Sarma JV, Zetoune F, Flierl MA, Perl M, Denk S, Weiss M, Schneider ME, Monk PN, Neff T, Mihlan M, Barth H, Gebhard F, Ward PA, Huber-Lang M (2013) Changes and regulation of the C5a receptor on neutrophils during septic shock in humans. J Immunol 190:4215\u20134225","journal-title":"J Immunol"},{"key":"2091_CR105","doi-asserted-by":"publisher","first-page":"e12500","DOI":"10.1111\/micc.12500","volume":"25","author":"I Vasileiadis","year":"2018","unstructured":"Vasileiadis I, Politou M, Dimopoulos S, Rovina N, Kyriakopoulou M, Kyriakoudi A, Tripodaki ES, Koutsouri T, Terpos E, Koulouris N, Koutsoukou A (2018) Variation of endothelium-related hemostatic factors during sepsis. Microcirculation 25:e12500","journal-title":"Microcirculation"},{"key":"2091_CR106","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","volume":"3","author":"S Verma","year":"2018","unstructured":"Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, Dyck JE, Uddin GM, Oudit GY, Mayoux E, Lehrke M, Marx N, Lopaschuk GD (2018) Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci 3:575\u2013587","journal-title":"JACC Basic Transl Sci"},{"key":"2091_CR107","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1269","volume":"4","author":"PA Ward","year":"2004","unstructured":"Ward PA (2004) The dark side of C5a in sepsis. Nat Rev Immunol 4:133\u2013142","journal-title":"Nat Rev Immunol"},{"key":"2091_CR108","doi-asserted-by":"publisher","first-page":"10591","DOI":"10.1038\/s41598-022-14961-w","volume":"12","author":"R Weckx","year":"2022","unstructured":"Weckx R, Goossens C, Derde S, Pauwels L, Vander Perre S, Van den Berghe G, Langouche L (2022) Efficacy and safety of ketone ester infusion to prevent muscle weakness in a mouse model of sepsis-induced critical illness. Sci Rep 12:10591","journal-title":"Sci Rep"},{"key":"2091_CR109","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/bja\/aer515","volume":"108","author":"TE Woodcock","year":"2012","unstructured":"Woodcock TE, Woodcock TM (2012) Revised starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth 108:384\u2013394","journal-title":"Br J Anaesth"},{"key":"2091_CR110","doi-asserted-by":"publisher","first-page":"101367","DOI":"10.1016\/j.diabet.2022.101367","volume":"48","author":"MZ Wu","year":"2022","unstructured":"Wu MZ, Chandramouli C, Wong PF, Chan YH, Li HL, Yu SY, Tse YK, Ren QW, Yu SY, Tse HF, Lam CSP, Yiu KH (2022) Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors. Diabetes Metab 48:101367","journal-title":"Diabetes Metab"},{"key":"2091_CR111","doi-asserted-by":"publisher","first-page":"836849","DOI":"10.3389\/fphar.2022.836849","volume":"13","author":"L Xie","year":"2022","unstructured":"Xie L, Xiao Y, Tai S, Yang H, Zhou S, Zhou Z (2022) Emerging roles of sodium glucose cotransporter 2 (SGLT-2) inhibitors in diabetic cardiovascular diseases: focusing on Immunity, inflammation and metabolism. Front Pharmacol 13:836849","journal-title":"Front Pharmacol"},{"key":"2091_CR112","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/dom.12090","volume":"15","author":"JF Yale","year":"2013","unstructured":"Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G (2013) Efficacy and safety of Canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15:463\u2013473","journal-title":"Diabetes Obes Metab"},{"key":"2091_CR113","doi-asserted-by":"publisher","first-page":"110206","DOI":"10.1016\/j.cellsig.2021.110206","volume":"90","author":"L Yang","year":"2022","unstructured":"Yang L, Liang B, Li J, Zhang X, Chen H, Sun J, Zhang Z (2022) Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK\/mTOR mediated autophagy pathway. Cell Signal 90:110206","journal-title":"Cell Signal"},{"key":"2091_CR114","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZI (2022) Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep 7:1463\u20131476","journal-title":"Kidney Int Rep"},{"key":"2091_CR115","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/ckj\/sfz042","volume":"12","author":"O Yilmaz","year":"2019","unstructured":"Yilmaz O, Afsar B, Ortiz A, Kanbay M (2019) The role of endothelial glycocalyx in health and disease. Clin Kidney J 12:611\u2013619","journal-title":"Clin Kidney J"},{"key":"2091_CR116","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1553-2712.2010.00713.x","volume":"17","author":"JG Younger","year":"2010","unstructured":"Younger JG, Bracho DO, Chung-Esaki HM, Lee M, Rana GK, Sen A, Jones AE (2010) Complement activation in emergency department patients with severe sepsis. Acad Emerg Med 17:353\u2013359","journal-title":"Acad Emerg Med"},{"key":"2091_CR117","doi-asserted-by":"publisher","first-page":"103833","DOI":"10.1016\/j.etap.2022.103833","volume":"91","author":"MS Zaghloul","year":"2022","unstructured":"Zaghloul MS, Elshal M, Abdelmageed ME (2022) Preventive empagliflozin activity on acute acetic acid-induced ulcerative colitis in rats via modulation of SIRT-1\/PI3K\/AKT pathway and improving colon barrier. Environ Toxicol Pharmacol 91:103833","journal-title":"Environ Toxicol Pharmacol"},{"key":"2091_CR118","doi-asserted-by":"publisher","first-page":"139548","DOI":"10.1016\/j.ijbiomac.2025.139548","volume":"295","author":"JH Zhan","year":"2025","unstructured":"Zhan JH, Wei J, Liu YJ, Wang PX, Zhu XY (2025) Sepsis-associated endothelial glycocalyx damage: a review of animal models, clinical evidence, and molecular mechanisms. Int J Biol Macromol 295:139548","journal-title":"Int J Biol Macromol"},{"key":"2091_CR119","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-024-01325-9","volume":"16","author":"R Zhang","year":"2024","unstructured":"Zhang R, Xie Q, Lu X, Fan R, Tong N (2024) Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. Diabetol Metab Syndr 16:99","journal-title":"Diabetol Metab Syndr"},{"key":"2091_CR120","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J (2018) Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated Inhibition of mitochondrial fission. Redox Biol 15:335\u2013346","journal-title":"Redox Biol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02091-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-02091-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02091-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:02:33Z","timestamp":1771639353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-02091-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":120,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2091"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-02091-4","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflict of interest"}},{"value":"KLL is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK139339). Unrelated to this work, KLL receives consulting fees from CareDx and speaker honoraria from Sanofi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}